TH1601007114A - "Loba Platin Crystal Preparation method And pharmaceutical use " - Google Patents
"Loba Platin Crystal Preparation method And pharmaceutical use "Info
- Publication number
- TH1601007114A TH1601007114A TH1601007114A TH1601007114A TH1601007114A TH 1601007114 A TH1601007114 A TH 1601007114A TH 1601007114 A TH1601007114 A TH 1601007114A TH 1601007114 A TH1601007114 A TH 1601007114A TH 1601007114 A TH1601007114 A TH 1601007114A
- Authority
- TH
- Thailand
- Prior art keywords
- pharmaceutical use
- crystal preparation
- loba
- platin
- compound
- Prior art date
Links
- 229950008991 Lobaplatin Drugs 0.000 title claims 2
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 2
- -1 Lobaplatin compound Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
Claims (2)
Publications (1)
Publication Number | Publication Date |
---|---|
TH1601007114A true TH1601007114A (en) | 2019-10-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TH1601007114A (en) | "Loba Platin Crystal Preparation method And pharmaceutical use " | |
TH1501003557A (en) | "The use of 3-carboxy-N-ethyl-N, N-dimethyl propan-1-aluminum Or the pharmacologically acceptable salt of this substance in the treatment of atherosclerosis. " | |
TH1501003256A (en) | Pharmaceutical constituents containing chloroprocaine - are the basis for their action. To be repeated in the spinal canal | |
TH1601001699A (en) | Ceftholosen's solid form | |
TH1501005347A (en) | S-Ketamine Hydrochloride Pharmaceutical Composition | |
TH1601006448A (en) | Muscle atrophy inhibitors containing quercetin glycosides | |
TH1701002633A (en) | Antigen-bound molecules made up of trymers of the TNF family ligand. | |
TH177127A (en) | Stabilized insulin glulisine formulation | |
TH177286A (en) | Steel plate | |
TH178566A (en) | The stable constituents of the neuroactive peptides | |
TH162724A (en) | Steel plate | |
TH178972A (en) | Alkylated cyclodextrin composition And the process for preparing And using the same | |
TH1601004226A (en) | Antibody molecules to PD-1 and their uses | |
TH175872A (en) | The use of a mixture of salt and sugar in the production of drugs used to treat the syndrome Vaginal prolapse or mammalian colposerosis | |
TH1701003780A (en) | Sulfonamides Pharmaceutical Composition | |
TH1601003237A (en) | ||
TH178633A (en) | Antibiotic composition | |
TH1701003406A (en) | Pharmaceutical formulation of tropomieosin-related kinase inhibitors (TRK). | |
TH1601006489A (en) | Pro-drak of 1,1 '- (1,6-dioxo-1,6-hexendaiyl) bis-D-proline. | |
TH1701002548A (en) | Long-acting pharmaceutical constituents for hepatitis C | |
TH182826A (en) | Thyazine compounds and their use for medical purposes | |
TH175588A (en) | KZ144 modified endolysin sequence | |
TH1701002664A (en) | Therapeutic combination for the treatment of drug-resistant bacterial infections. | |
TH178578A (en) | Vaccine composition against dengue virus | |
TH1501005024A (en) | Pharmaceutical constituents for the treatment of fungal infections. |